̽��ֱ�� of Cambridge - Department of Oncology

Under the bonnet at Dawn, the UK's fastest AI supercomputer

hcf38 — Mon, 17 Mar 2025 15:58:08 +0000

How AI supercomputer, Dawn, is being used to tackle some of the most pressing issues facing humanity.

Cambridge Festival Speaker Spotlight: Dr Mireia Crispin

zs332 — Wed, 12 Feb 2025 14:03:02 +0000

Dr Mireia Crispin is an Assistant Professor in the Department of Oncology at the ̽��ֱ�� of Cambridge and leads a research group focusing on the development of multi-omic data integration models to understand how tumours evolve and respond to treatment.

̽��ֱ��Cambridge Awards 2024 for Research Impact and Engagement

zs332 — Mon, 03 Feb 2025 10:27:01 +0000

Meet the winner of the Cambridge Awards 2024 for Research Impact and Engagement and learn more about their projects.

Cambridge's Raj Jena becomes UK's first Professor of AI in radiotherapy

sb726 — Thu, 17 Oct 2024 08:00:31 +0000

̽��ֱ��creation of the new Clinical Professorship signals the importance of AI in the fight against cancer and builds on the ̽��ֱ��’s work to apply the latest technology to the world’s major challenges.

Ten Cambridge scientists elected as Fellows of the Royal Society 2024

Anonymous — Thu, 16 May 2024 08:51:02 +0000

̽��ֱ��Royal Society is a self-governing Fellowship of many of the world’s most distinguished scientists drawn from all areas of science, engineering and medicine.

̽��ֱ��Society’s fundamental purpose, as it has been since its foundation in 1660, is to recognise, promote and support excellence in science and to encourage the development and use of science for the benefit of humanity.

This year, over 90 researchers, innovators and communicators from around the world have been elected as Fellows of the Royal Society for their substantial contribution to the advancement of science. Nine of these are from the ̽��ֱ�� of Cambridge.

Sir Adrian Smith, President of the Royal Society said: “I am pleased to welcome such an outstanding group into the Fellowship of the Royal Society.

“This new cohort have already made significant contributions to our understanding of the world around us and continue to push the boundaries of possibility in academic research and industry.

“From visualising the sharp rise in global temperatures since the industrial revolution to leading the response to the Covid-19 pandemic, their diverse range of expertise is furthering human understanding and helping to address some of our greatest challenges. It is an honour to have them join the Fellowship.”

̽��ֱ��Fellows and Foreign Members join the ranks of Stephen Hawking, Isaac Newton, Charles Darwin, Albert Einstein, Lise Meitner, Subrahmanyan Chandrasekhar and Dorothy Hodgkin.

̽��ֱ��new Cambridge fellows are:

Professor Sir John Aston Kt FRS

Aston is the Harding Professor of Statistics in Public Life at the Statistical Laboratory, Department of Pure Mathematics and Mathematical Statistics, where he develops techniques for public policy and improves the use of quantitative methods in public policy debates.

From 2017 to 2020 he was the Chief Scientific Adviser to the Home Office, providing statistical and scientific advice to ministers and officials, and was involved in the UK’s response to the Covid pandemic. He was knighted in 2021 for services to statistics and public policymaking, and is a Fellow of Churchill College.

Professor Sarah-Jayne Blakemore FBA FMedSci FRS

Blakemore is the Professor of Psychology and Cognitive Neuroscience, Department of Psychology, and leader of the Developmental Cognitive Neuroscience Group. Her research focuses on the development of social cognition and decision making in the human adolescent brain, and adolescent mental health.

Blakemore has been awarded several national and international prizes for her research, and is a Fellow of the British Academy, the American Association of Psychological Science and the Academy of Medical Sciences.

Professor Patrick Chinnery FMedSci FRS

Chinnery is Professor of Neurology and head of the ̽��ֱ��’s Department of Clinical Neurosciences, and a Fellow of Gonville & Caius College. He was appointed Executive Chair of the Medical Research Council last year, having previously been MRC Clinical Director since 2019.

His principal research is the role of mitochondria in human disease and developing new treatments for mitochondrial disorders. Chinnery is a Wellcome Principal Research Fellow with a lab based in the MRC Mitochondrial Biology Unit and jointly chairs the NIHR BioResource for Translational Research in Common and Rare Diseases. He is a Fellow of the Academy of Medical Sciences.

Professor Rebecca Fitzgerald OBE FMedSci FRS

Fitzgerald is Professor of Cancer Prevention in the Department of Oncology and the inaugural Director of the ̽��ֱ��’s new Early Cancer Institute, which launched in 2022. She is a Fellow of Trinity College.

Her pioneering work to devise a first-in-class, non-endoscopic capsule sponge test for identifying individuals at high risk for oesophageal cancer has won numerous prizes, including the Westminster Medal, and this test is now being rolled out in the NHS and beyond by her spin-out Cyted Ltd.

Professor David Hodell FRS

Hodell is the Woodwardian Professor of Geology and Director of the Godwin Laboratory for Palaeoclimate Research in the Department of Earth Sciences, and a Fellow of Clare College.

A marine geologist and paleoclimatologist, his research focuses on high-resolution paleoclimate records from marine and lake sediments, as well as mineral deposits, to better understand past climate dynamics. Hodell is a fellow of the American Geophysical Union and the American Association for the Advancement of Science. He has received the Milutin Milankovic Medal.

Professor Eric Lauga FRS

Lauga is Professor of Applied Mathematics in the Department of Applied Mathematics and Theoretical Physics, where his research is in fluid mechanics, biophysics and soft matter. Lauga is the author, or co-author, of over 180 publications and currently serves as Associate Editor for the journal Physical Review Fluids.

He is a recipient of three awards from the American Physical Society: the Andreas Acrivos Dissertation Award in Fluid Dynamics, the François Frenkiel Award for Fluid Mechanics and the Early Career Award for Soft Matter Research. He is a Fellow of the American Physical Society and of Trinity College.

Professor George Malliaras FRS

Malliaras is the Prince Philip Professor of Technology in the Department of Engineering, where he leads a group that works on the development and translation of implantable and wearable devices that interface with electrically active tissues, with applications in neurological disorders and brain cancer.

Research conducted by Malliaras has received awards from the European Academy of Sciences, the New York Academy of Sciences, and the US National Science Foundation among others. He is a Fellow of the Materials Research Society and of the Royal Society of Chemistry.

Professor Lloyd Peck FRI FRSB FRS

Peck is a marine biologist at the British Antarctic Survey and a fellow at Wolfson College, Cambridge.

He identified oxygen as a factor in polar gigantism and identified problems with protein synthesis as the cause of slow development and growth in polar marine species. He was awareded a Polar Medal in 2009, the PLYMSEF Silver medal in 2015 and an Erskine Fellowship at the ̽��ֱ�� of Canterbury, Christchurch in 2016-2017.

Professor Oscar Randal-Williams FRS

Randal-Williams is the Sadleirian Professor of Pure Mathematics in the Department of Pure Mathematics and Mathematical Statistics.

He has received the Whitehead Prize from the London Mathematical Society, a Philip Leverhulme Prize, the Oberwolfach Prize, the Dannie Heineman Prize of the Göttingen Academy of Sciences and Humanities, and was jointly awarded the Clay Research Award.

Randal-Williams is one of two managing editors of the Proceedings of the London Mathematical Society, and an editor of the Journal of Topology.

Professor Mihaela van der Schaar FRS

Van der Schaar is the John Humphrey Plummer Professor of Machine Learning, Artificial Intelligence and Medicine in the Departments of Applied Mathematics and Theoretical Physics, Engineering and Medicine.

She is the founder and director of the Cambridge Centre for AI in Medicine, and a Fellow at ̽��ֱ��Alan Turing Institute. Her work has received numerous awards, including the Oon Prize on Preventative Medicine, a National Science Foundation CAREER Award, and the IEEE Darlington Award.

Van der Schaar is credited as inventor on 35 US patents, and has made over 45 contributions to international standards for which she received three ISO Awards. In 2019, a Nesta report declared her the most-cited female AI researcher in the UK.

Ten outstanding Cambridge researchers have been elected as Fellows of the Royal Society, the UK’s national academy of sciences and the oldest science academy in continuous existence.

Royal Society

̽��ֱ��Royal Society in central London

̽��ֱ��text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright © ̽��ֱ�� of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Report highlights inequalities and hidden suffering among people living with breast cancer

cjb250 — Mon, 15 Apr 2024 22:31:36 +0000

Many people with breast cancer ‘systematically left behind’, say researchers in Lancet Commission led by Professor Charlotte Coles.

Radiotherapy boost cuts breast cancer treatment time by at least one week

cjb250 — Mon, 03 Jul 2023 08:04:03 +0000

Results from the IMPORT HIGH trial, published in ̽��ֱ��Lancet, show that giving some breast cancer patients a targeted additional dose of radiotherapy at the same time as treatment to the whole breast (known as simultaneous integrated boost or SIB) cuts the time taken to complete treatment by at least one week.

̽��ֱ��trial, funded by Cancer Research UK and the National Institute of Health Research and Care Research (NIHR), found that SIB radiotherapy given at the right dose works just as well as existing radiotherapy techniques in reducing the risk of the cancer returning in the treated breast.

̽��ֱ��chance of the cancer returning to the treated breast remained very low after 5 years across all treatment groups. Patients given the lower dose of SIB radiotherapy reported similar rates of side-effects, like breast hardening or firmness, as those who received the standard sequential radiotherapy schedule.

Currently, women with a higher than average risk of cancer coming back in their treated breast are given an additional radiotherapy dose to the original site of the tumour after radiotherapy is given to the entire breast. This approach, known as sequential boost, maximises the chances that any remaining cancer cells are removed from the breast.

But it takes longer for women to complete sequential boost radiotherapy, requiring them to attend more hospital appointments. In the UK, many women requiring breast boost radiotherapy are given 4 weeks of radiotherapy – 3 weeks to the whole breast with 1 week boost afterwards. In some countries, women are given 6.5 weeks of radiotherapy – 5 weeks of whole breast radiotherapy with 1-1.5 weeks boost afterwards. SIB radiotherapy cuts this down to just 3 weeks in total.

A boost treatment also increases the chance of having potentially long term side-effects after treatment, including changes in shape, size and texture of the breast that can affect women’s self-esteem and wellbeing.

In total, 2,617 patients at 76 centres took part in the trial. Patients were divided into three groups. ̽��ֱ��first group received whole breast radiotherapy with a sequential boost over 4.5 weeks in total. ̽��ֱ��second and third groups each received two different doses of SIB radiotherapy. Patients received whole breast radiotherapy with a simultaneous boost of either lower or higher dose a dose over 3 weeks in total. There was no advantage shown for those who received the higher boost dose it also led to slightly increased rates of side effects.

Professor of Breast Cancer Clinical Oncology at Cambridge ̽��ֱ��, NIHR Professor and chief investigator for the trial, Professor Charlotte Coles, said: “Some women have to live with permanent breast changes after radiotherapy which may affect their well-being. With SIB, we can deliver high-quality effective radiotherapy whilst minimising toxicity from it.

“This is a careful step towards even shorter courses of radiotherapy that include more complex techniques. By delivering more targeted boost radiotherapy over shorter time periods, women can get on with their lives more quickly."

̽��ֱ��NIHR-funded FAST Forward trial, which was also led by the ICR-CTSU and reported results in 2020, showed that whole breast radiotherapy could be given over a week. Researchers are now hoping to run another clinical trial to find out if SIB radiotherapy can be delivered to patients requiring a boost in just one week.

Professor Judith Bliss, Professor of Clinical Trials at ̽��ֱ��Institute of Cancer Research, London, Director of the Cancer Research UK-funded Clinical Trials and Statistics Unit at the ICR which is managing the IMPORT HIGH trial, said: “For some patients who have a higher risk of seeing their cancer return in the treated breast, delivering an extra, targeted boost of radiotherapy to breast tissue close to the original tumour site is an effective way to lower that risk and help keep cancer from returning to the breast.

"IMPORT HIGH has uncovered how we can streamline our delivery of these radiotherapy boosts - giving them simultaneously with whole breast radiotherapy - without impacting the effectiveness of treatment, or causing patients additional side effects. We hope this trial will change clinical practice - allowing women to benefit from sophisticated radiotherapy delivery with shorter treatment times and fewer hospital visits."

̽��ֱ��team hope that SIB radiotherapy could reduce the costs for patients travelling to hospital and cut the time taken to undergo treatment and recovery. It could be quickly adopted by the NHS and health systems worldwide as standard radiotherapy equipment is used, freeing up valuable appointment visits that could be used to treat more cancer patients sooner.

Chief Executive of Cancer Research UK, Michelle Mitchell, said: “At a time when health services across the UK are facing chronic staff shortages in cancer services, we need to look at new ways to get more patients treated as quickly as possible. In addition to training up more staff, more precise forms of radiotherapy can help to reduce the number of people who are waiting too long to begin vital treatment.

“Trials like IMPORT HIGH are leading the way in delivering smarter radiotherapy with existing technology. We hope that treatment centres across the UK and globally will rapidly adopt this approach to beat breast cancer sooner and give patients more precious time with their loved ones.”

Reference
Coles, CE et al. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet; 8 June 2023; DOI: 10.1016/S0140-6736(23)00619-0

Adapted from a press release by Cancer Research UK.

Treatment times for radiotherapy could be reduced for some early breast cancer patients, according to a trial led by ̽��ֱ�� of Cambridge and ̽��ֱ��Institute of Cancer Research, London.

This is a careful step towards even shorter courses of radiotherapy that include more complex techniques. By delivering more targeted boost radiotherapy over shorter time periods, women can get on with their lives more quickly

Charlotte Coles

Patrick Harrison/Cancer Research UK

Professor Charlotte Coles

Helen Lee (46) from Mepal near Cambridge

In October 2013, Helen Lee first noticed an unusual twinge in her right breast and had a hunch that something wasn’t right. Her GP couldn’t feel anything when she examined Helen but referred her to the Breast Unit at Addenbrooke’s Hospital for a mammogram to reassure her.

But, at the young age of 36, Helen was diagnosed with breast cancer. ̽��ֱ��mammogram revealed a tumour just over 2cm in size located deep in her breast tissue. She remembered:

“I felt quite relieved because I knew there was something wrong. And my surgeon said it was so deep I wouldn't have felt it. So I was actually really lucky otherwise I would have come in at 51 for screening and it might not have been treatable by then.”

Helen had surgery a few weeks after her diagnosis, followed by a course of chemotherapy. When she was due to begin radiotherapy treatment she was asked if she would like to take part in the IMPORT HIGH trial. Helen was assigned to a group receiving a targeted radiotherapy boost delivered simultaneously during her whole breast radiotherapy treatment, which reduced her treatment from 23 sessions over 4.5 weeks to 15 sessions over 3 weeks.

After undergoing surgery, chemotherapy and radiotherapy treatment, Helen has now been clear of cancer for nearly 10 years. Since her diagnosis and treatment, she has taken part regularly in Cancer Research UK Race for Life, Pretty Muddy and Shine Night Walk events in Cambridge, Bedford and Stamford, fundraising for life-saving research into future treatments for cancer patients.

Reflecting on her cancer journey, Helen said: “One thing that really struck me, at one of the first Cambridge Race for Life events that I did after my diagnosis, was watching the screen on Parker's Piece where they're playing the films where the scientists are talking about what they've been working on.

“I felt so overwhelmed that all of the people there that day were part of saving my life, and that all the people who took part in trials 10 years ago, 15 years ago, 20 years ago, everything they've done meant that I survived my cancer.”

̽��ֱ��text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright © ̽��ֱ�� of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – as here, on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes

Cambridge researchers elected to Academy of Medical Sciences Fellowship 2023

lw355 — Thu, 18 May 2023 08:00:52 +0000

̽��ֱ��new Fellows have been elected to the Academy in recognition of their exceptional contributions to the advancement of biomedical and health science, cutting-edge research discoveries and translating developments into benefits for patients and wider society.

They join a prestigious Fellowship of 1,400 esteemed researchers who are central to the Academy’s work. This includes providing career support to the next generation of researchers and contributing to the Academy’s influential policy work to improve health in the UK and globally.

Professor Dame Anne Johnson PMedSci, President of the Academy of Medical Sciences, said: “These new Fellows are pioneering biomedical research and driving life-saving improvements in healthcare. It’s a pleasure to recognise and celebrate their exceptional talent by welcoming them to the Fellowship.

“This year, we are celebrating our 25th anniversary. ̽��ֱ��Fellowship is our greatest asset, and their broad expertise and dynamic ability has shaped the Academy to become the influential, expert voice of health. As we look to the future, the collective wisdom our new Fellows bring will be pivotal in achieving our mission to create an open and progressive research sector to improve the health of people everywhere.”

̽��ֱ��new Cambridge Fellows are:

Professor Charlotte Coles FMedSci

Professor of Breast Cancer Clinical Oncology, Department of Oncology, NIHR Research Professor and Director of Cancer Research UK RadNet Cambridge

Professor Coles leads practice-changing breast radiotherapy trials, has influenced international hypofractionation policy and is addressing global health, gender and equity challenges within the Lancet Breast Cancer Commission.

“It’s an honour to be elected as a new Fellow of the Academy of Medical Sciences. This is a result of research collaborations in Cambridge, the UK and internationally and I’d like to thank these wonderful colleagues, especially patient advocates,” said Coles.

“I hope to contribute to the Academy’s work to increase equity, diversity and inclusion within leadership roles, including lower- and middle-income countries, to enrich research and improve the culture in Medical Sciences.”

Professor Emanuele Di Angelantonio FMedSci

Professor of Clinical Epidemiology and Donor Health, Department of Public Health and Primary Care, and Head of Health Data Science Centre, Human Technopole (Milan)

Professor Di Angelantonio’s research has focused on addressing major clinical and public health priorities in cardiovascular disease (CVD) and transfusion medicine. His election recognises his many contributions both in helping resolve important controversies in CVD prevention strategies and in improving the safety and efficiency of blood donation.

“I am delighted and honoured to be elected to the Fellowship of the Academy of Medical Sciences, which I recognise is an outcome of the collaborations with many colleagues in UK and worldwide,” said Di Angelantonio.

“Research excellence across medical sciences and translation to health improvements has been at the centre of the Academy’s mission and I am very pleased to now be able to contribute to fulfilling this aim as a Fellow.”

Dr Rita Horvath FMedSci

Director of Research in Genetics of Rare Neurological Disorders in the Department of Clinical Neurosciences and Honorary Consultant in Neurology

Dr Horvath is an academic neurologist using genomics and biochemistry to diagnose rare, inherited neurological disorders, with a focus on mitochondrial diseases. Throughout her career she has combined fundamental experimental work with clinical studies. She pioneered the development and implementation of next generation sequencing in the diagnosis of rare neurogenetic diseases in the UK, leading to precision genetic approaches. She has established extensive international collaborations, having impact in Europe, but also for underserved groups in countries where such expertise is lacking.

“I am delighted and honoured to be elected to this Fellowship, which recognises the impact of my work. I would not have achieved it without the support of my excellent colleagues and research team, for which I give my sincere thanks,” said Horvath.

“As a Hungarian woman working in different countries before I arrived in the UK in 2007, I feel particularly proud of this award, which I recognise is an outcome of the open and fair research environment in Cambridge. This Fellowship enables me to further expand my research to develop effective treatments for patients with rare inherited neurological diseases.”

Professor Eric Miska FMedSci

Herchel Smith Chair of Molecular Genetics and Head of Department of Biochemistry, Affiliated Senior Group Leader at the Gurdon Institute, Associate Faculty at the Wellcome Sanger Institute and Fellow of St John’s College

Professor Miska is a molecular geneticist who has carried out pioneering work on RNA biology. His work led to fundamentally new insights into how small RNA molecules control our genes and protect organisms from selfish genes and viruses, and how RNA can carry heritable information across generations. Miska is Founder and Director of STORM Therapeutics Ltd, which creates novel therapies that inhibit RNA modifying enzymes for use in oncology and other diseases.

“Wonderful recognition of the work of an amazing team of researchers I have the pleasure to work with,” said Miska. “Most of our research has been done using the roundworm C. elegans. As Friedrich Nietzsche wrote in Thus Spoke Zarathustra: ‘You have evolved from worm to man, but much within you is still worm’.”

Professor Serena Nik-Zainal FMedSci

NIHR Research Professor, Professor of Genomic Medicine and Bioinformatics, Department of Medical Genetics and Early Cancer Institute, and Honorary Fellow of Murray Edwards College

Professor Nik-Zainal’s research is focused on investigating the vast number of mutations that occur in human DNA from birth, causing patterns called ‘mutational signatures’, and the associated physiological changes to cellular function, in progressive diseases such as cancer and neurodegeneration. She uses a combination of experimental and computational methods to understand biology and to develop clinical tests for early detection and precision diagnostics. Her team also builds computational tools to enable genomic advances become more accessible across the NHS.

“What an honour it is to be elected to the Fellowship. This is a wonderful recognition of the work from my team,” said Nik-Zainal. “We are thrilled and hugely indebted to all our inspiring collaborators, supporters and patients, who have shared in our passion and joined us on our path, exploring biomedical science and translating insights into patient benefit.”

Professor Julian Rayner FMedSci

Director of the Cambridge Institute for Medical Research, School of Clinical Medicine, Honorary Faculty at the Wellcome Sanger Institute, and Director of Wellcome Connecting Science

Professor Rayner’s research has made significant contributions to our understanding of how malaria parasites recognise and invade human red blood cells to cause disease. His work has helped to identify new vaccine targets, such as a protein essential for red blood cell invasion that is now in early stage human vaccine testing, and inform antimalarial drug development, through co-leading the first ever genome-scale functional screens in malaria parasites. He collaborates closely with researchers in malaria-endemic countries and is strongly committed to engaging public audiences with the process and outcomes of science.

“Malaria is a devastating and too often forgotten disease that still kills more than half a million children every year. Tackling it requires deep collaboration and working across disciplines. I’m enormously honoured by this announcement, which reflects not my work but the work of all the talented people I’ve been lucky enough to host in my lab, and collaborations with friends and colleagues across the world,” said Rayner.

“I’m excited to become a Fellow of the Academy of Medical Sciences because I strongly share their conviction that science is not just for scientists. I believe that dialogue, learning and public engagement are all fundamental and essential parts of the research process, and I look forward to contributing to their leading role in these areas.”

Professor James Rowe FMedSci

Professor of Cognitive Neurology, Department of Clinical Neurosciences, and MRC Cognition and Brain Sciences Unit

Professor Rowe leads a highly interdisciplinary research team at the Cambridge Centre for Frontotemporal Dementia and at Dementias Platform UK to improve the diagnosis and treatment of people affected by dementia. His work integrates cognitive neuroscience, brain imaging, fluidic biomarkers, computational models and neuropathology for experimental medicine studies and clinical trials. He is motivated by his busy clinical practice and the need for better diversity and inclusivity throughout medical research.

“I am delighted and honoured to be elected to the Fellowship of the Academy of Medical Sciences. It is a testament to the many wonderful colleagues and students I have been fortunate to work with, and to inspirational mentors,” said Rowe.

“Research excellence, and translation of research for direct human benefit, comes from innovation and collaboration in diverse cross-disciplinary teams. I believe in the vision and values of the Academy as the route to better health for all.”

In addition, two researchers from the wider community have also been elected:

Dr Trevor Lawley FMedSci, Senior Group Leader, Wellcome Sanger Institute and Chief Scientific Officer, Microbiotica

Professor Ben Lehner FRS FMedSci, Senior Group Leader, Human Genetics Programme, Wellcome Sanger Institute

Seven Cambridge ̽��ֱ�� researchers are among the 59 biomedical and health researchers elected to the Academy of Medical Sciences Fellowship.

As we look to the future, the collective wisdom our new Fellows bring will be pivotal in achieving our mission to create an open and progressive research sector to improve the health of people everywhere

Professor Dame Anne Johnson, President of the Academy of Medical Sciences

Clockwise from top left: E. Di Angelantonio, J. Rayner, J. Rowe, R. Horvath, S. Nik-Zainal, E. Miska, C. Coles

̽��ֱ��text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Images, including our videos, are Copyright © ̽��ֱ�� of Cambridge and licensors/contributors as identified. All rights reserved. We make our image and video content available in a number of ways – as here, on our main website under its Terms and conditions, and on a range of channels including social media that permit your use and sharing of our content under their respective Terms.

Yes